View Cart (0 items)
Pharmaceutical

AstraZeneca Eliminating Over 500 Delaware R&D Jobs

March 03, 2010
/ Print / Reprints /
| Share More
/ Text Size+

Pharmaceutical company AstraZeneca PLC is reorganizing its global research and development operations and eliminating roughly 1,800 R&D jobs as part of a previously announced cost-cutting plan, according to the Associated Press. About 550 jobs will be eliminated at AstraZeneca''s U.S. headquarters in Delaware as it moves primary research and development elsewhere, the London-based company said. AstraZeneca also said it will close research sites in the United Kingdom and Sweden, and that about 3,500 R&D jobs will be affected as part of a plan announced in January to cut 8,000 jobs, or 12 percent of its workforce, by 2014. The termination of psychiatric laboratory research in Delaware represents about one-third of the company''s R&D work force in the state, where future R&D efforts will focus on shepherding drugs through clinical trials and regulatory approval. AstraZeneca said its facilities in Boston will see some growth as employees transfer from other sites.

You must login or register in order to post a comment.